High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Li, Mei ^a   Luo, Rong Zhen ^a   Chen, Jie Wei ^a   Cao, Yun ^a   Lu, Jia Bin ^a   He, Jie Hua ^a   Wu, Qiu Liang ^a   Cai, Mu Yan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN P300; E1A ASSOCIATED P300 PROTEIN; EP300 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; AGED; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; E1A-ASSOCIATED P300 PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 78650782799     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-5     Document Type: Article

References (31)

1. Lau WY, Lai EC, Lau SH. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2009, 8:124-133.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
3. Cabibbo G, Craxi A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 14:352-355.
4. Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 31:179-193. 10.1016/j.mam.2010.02.007, 20176048.
5. Kundu TK, Palhan VB, Wang Z, An W, Cole PA, Roeder RG. Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol Cell 2000, 6:551-561. 10.1016/S1097-2765(00)00054-X, 11030335.
6. Vo N, Goodman RH. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 2001, 276:13505-13508.
7. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000, 14:1553-1577.
8. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong JM, Iwama T, Miyaki M. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996, 12:1565-1569.
9. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000, 24:300-303. 10.1038/73536, 10700188.
10. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, et al. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002, 62:141-151.
11. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, Medrano EE. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002, 62:6231-6239.
12. Fang Z, Fu Y, Liang Y, Li Z, Zhang W, Jin J, Yang Y, Zha X. Increased expression of integrin beta1 subunit enhances p21WAF1/Cip1 transcription through the Sp1 sites and p300-mediated histone acetylation in human hepatocellular carcinoma cells. J Cell Biochem 2007, 101:654-664. 10.1002/jcb.21223, 17211849.
13. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 38:5366-5383. 10.1093/nar/gkq285, 2938198, 20423907.
14. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003, 63:7638-7640.
15. Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW, Veltri RW. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 2008, 68:1097-1104. 10.1002/pros.20772, 18459105.
16. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593. 10.1200/JCO.2006.09.4565, 17577038.
17. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997, 80:1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9, 9351551.
18. Han L, Lu J, Pan L, Wang X, Shao Y, Han S, Huang B. Histone acetyltransferase p300 regulates the transcription of human erythroid-specific 5-aminolevulinate synthase gene. Biochem Biophys Res Commun 2006, 348:799-806. 10.1016/j.bbrc.2006.07.147, 16904069.
19. Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, Xie D. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 101:1543-1549. 10.1111/j.1349-7006.2010.01560.x, 20367640.
20. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007, 60:1112-1116. 10.1136/jcp.2006.044537, 2014838, 17182662.
21. Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S, Kimura S, Kimura W. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol 2007, 60:1205-1210. 10.1136/jcp.2005.029165, 2095491, 17720775.
22. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell Res 2007, 17:324-332. 10.1038/cr.2007.10, 17372613.
23. Borrow J, Stanton VP, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996, 14:33-41. 10.1038/ng0996-33, 8782817.
24. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000, 6:512-518.
25. Zhang C, Guo X, Jiang G, Zhang L, Yang Y, Shen F, Wu M, Wei L. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int J Cancer 2008, 123:998-1004. 10.1002/ijc.23650, 18546260.
26. Fermento ME, Gandini NA, Lang CA, Perez JE, Maturi HV, Curino AC, Facchinetti MM. Intracellular distribution of p300 and its differential recruitment to aggresomes in breast cancer. Exp Mol Pathol 88:256-264. 10.1016/j.yexmp.2010.01.007, 20097195.
27. De-Carvalho MC, Chimelli LM, Quirico-Santos T. Modulation of fibronectin expression in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis. Braz J Med Biol Res 1999, 32:583-592. 10.1590/S0100-879X1999000500012, 10412570.
28. Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat 2003, 78:193-204. 10.1023/A:1022930710850, 12725419.
29. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000, 89:2266-2273. 10.1002/1097-0142(20001201)89:11<2266::AID-CNCR15>3.0.CO;2-0, 11147597.
30. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008, 7:237-257.
31. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. 10.1002/hep.20933, 16250051.